Page last updated: 2024-12-07
dianhydro-3,4-diacetylgalactitol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dianhydro-3,4-diacetylgalactitol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 99960 |
MeSH ID | M0090533 |
Synonyms (19)
Synonym |
---|
dadag |
diacdag |
3,4-diacetyl-1,2-5,6-dianhydro-dulcitol |
brn 5038885 |
galactitol, 1,2:5,6-dianhydro-, diacetate |
dianhydro-3,4-diacetylgalactitol |
3,4-diacetyldianhydrogalactitol |
nsc-292297 |
nsc292297 |
57230-48-5 |
galactitol,2:5,6-dianhydro-, diacetate |
[2-acetyloxy-1,2-bis(oxiran-2-yl)ethyl] acetate |
diacetyl-diepoxydulcitol |
nsc 292297 |
diacetyldianhydrodulcitol |
diacetyldianhydrogalactitol |
1,2:5,6-dianhydro-3,4-diacetylgalactitol |
DTXSID20972730 |
3,4-di-o-acetyl-1,2:5,6-dianhydrohexitol |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" We conclude that in addition to the distance between the AUCs of the LD10 and of the human starting dose, interspecies pharmacokinetic differences should also be considered in planning the rate of dose escalation." | ( The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol. Csetényi, J; Erdélyi-Tóth, V; Kanyár, B; Kerpel-Fronius, S; Kovács, P; Somfai-Relle, S; Ujj, G, 1988) | 0.27 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" The nadir of the intestinal damage and the time of regeneration were influenced both by the dose and the dosage schedule of the drugs." | ( Biochemical changes of intestinal epithelial cells induced by cytostatic agents in rats. Kralovánszky, J; Prajda, N, 1985) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 11 (68.75) | 18.7374 |
1990's | 1 (6.25) | 18.2507 |
2000's | 4 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.81
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.81) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |